Laminin Cloned For Wound Applications

24 September 1997

- BioStratum has achieved its goal of developing a recombinant,functional form of a laminin molecule. Laminins are complex extracellular proteins which may have utility in the treatment of deep wounds, severe burns or traumatic injury of nerves and blood vessels. BioStratum has already signed an agreement with Shiseido of Japan to develop skin regeneration products based on laminin-5. The company is also working on laminin-2 and laminin-8, which target nerves and blood vessels respectively.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight